Ikarian Capital’s KalVista Pharmaceuticals KALV Stock Holding History

Ikarian Capital’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-400,000	Closed	-$4.87M	–	201
2025 Q3	$4.87M	Hold	400,000	–	–	0.49%	50
2025 Q2	$4.52M	Buy	+400,000	New	+$4.89M	0.87%	35
2021 Q1	–	Sell	-145,500	Closed	-$2.76M	–	317
2020 Q4	$2.76M	Buy	+145,500	New	+$2.5M	0.12%	137

Other funds holding KALV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Ikarian Capital's KALV Position: Q2 2026 in Review

Ikarian Capital sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 35,119 shares — an estimated $707K sold.

Ikarian Capital first reported a position in KALV in Q4 2019 and held it in 16 quarters. The position peaked at $20.2M in Q4 2020. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

Ikarian Capital reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Ikarian Capital sold 35,119 KalVista Pharmaceuticals shares in Q2 2026, an estimated $707K.
Ikarian Capital first reported a position in KalVista Pharmaceuticals in Q4 2019 and held it in 16 quarters.
Ikarian Capital's KalVista Pharmaceuticals position peaked at $20.2M in Q4 2020.
1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.